/
JBIO
$24.71+$0.90 (+3.78%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.5B
64M shares
52-week range
$6.67 – $28.00
85% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$14.57
Jade Biosciences, Inc. Common Stock
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
www.jadebiosciences.com- Employees
- 55
- IPO / List date
- Apr 29, 2025
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds JBIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 135,039 | $1.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded JBIO yet.
